Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	78.50B -66.7%
Revenue (ttm)	2.30B +11.3%
Net Income	-16.14B
EPS	n/a
Shares Out	6.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,803
Open	11,130
Previous Close	11,130
Day's Range	10,750 - 12,090
52-Week Range	10,750 - 48,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2025, Organoidsciences's revenue was 2.41 billion, an increase of 23.21% compared to the previous year's 1.95 billion. Losses were -15.37 billion, 36.6% more than in 2024.